Demand for therapeutic recombinant proteins will eventually exceed current production capabilities. This is a major driver in further understanding Chinese Hamster Ovary (CHO) cell biology, which is the cell line of choice for producing these proteins. Further R&D into CHO is expected to improve production capacity.
Would you like to access the complete CEP Article?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
AIChE Membership
You must be an AIChE member to view this article. Join now.
Copyright Permissions
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.